Skip to content

Dexcom Inc

Dexcom

DXCM · NASDAQ

Healthcare

Catalog as of September 15, 2026. Not a live market feed.

Fiscal Year
2025
Revenue
$4.7B
Assets
$6.3B
SEC filing
DEF 14A
Filed
April 15, 2026

Executive Compensation

Compensation reported for Dexcom’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.

Jacob Leach

President & Chief Executive Officer

$8M

Reported total · FY2025 · SCT Total as filed

Source: DEF 14A Summary Compensation Table, filed April 15, 2026.

Salary
$769K
Stock Awards
$5.9M
Incentives
$1.2M
Other
$116K

Historical Compensation

Jacob Leach total compensation, fiscal years 2023–2025.

Year-by-year total compensation
Fiscal YearSalaryTotal Compensation
2025$768,962$7,985,960
2024$682,498$5,922,271
2023$625,053$4,938,023

Named Executive Officers

Source information

Company
Dexcom Inc
Ticker
DXCM · NASDAQ
Filing type
DEF 14A
Fiscal year
2025
Filing date
April 15, 2026
SEC accession number
0001093557-26-000061

Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing

Related Companies